Supernus Pharmaceuticals financials
$43.97−1.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $219.1M | $207.7M | $211.6M | $192.1M | $165.5M | $149.8M | $174.2M | $175.7M | $168.3M | $143.6M | $164.3M | $153.9M |
| Gross profit | $185.4M | $184.3M | $188.6M | $173.1M | $148.6M | $134.1M | $148.1M | $158.1M | $150.4M | $127.3M | $144.7M | $134.3M |
| Gross margin | 84.6% | 88.7% | 89.1% | 90.1% | 89.8% | 89.5% | 85.0% | 90.0% | 89.4% | 88.6% | 88.1% | 87.3% |
| Operating income | -$58.0M | -$8.3M | -$3.9M | -$60.2M | $12.1M | -$10.3M | $21.4M | $40.8M | $22.6M | -$3.2M | -$996.0K | $8.1M |
| Net income | -$58.4M | -$2.3M | -$4.1M | -$45.1M | $22.5M | -$11.8M | $15.3M | $38.5M | $19.9M | $124.0K | $1.2M | -$16.0M |
| Net margin | −26.6% | −1.1% | −1.9% | −23.5% | 13.6% | −7.9% | 8.8% | 21.9% | 11.8% | 0.1% | 0.7% | −10.4% |
| Diluted EPS | $-1.01 | $-0.04 | $-0.07 | $-0.80 | $0.40 | $-0.21 | $0.27 | $0.69 | $0.36 | $0.00 | $0.02 | $-0.29 |
| EBITDA | $22.7M | $20.2M | $21.1M | -$35.4M | $33.5M | $17.8M | $40.3M | $60.9M | $43.3M | $17.6M | $19.0M | $29.5M |
| Operating cash flow | -$4.8M | $66.5M | $19.9M | -$61.7M | $58.5M | $30.6M | $44.4M | $53.5M | $35.6M | $38.4M | $43.6M | $37.2M |
| Free cash flow | -$5.4M | $66.5M | $19.4M | -$61.8M | $58.1M | $30.3M | $44.2M | $53.3M | $35.6M | $38.2M | $43.6M | $37.0M |
| Diluted shares | 58.1M | 57.6M | 56.7M | 56.6M | 56.6M | 55.9M | 56.5M | 56.0M | 55.7M | 55.6M | 50.5M | 54.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $180.0M | $184.9M | $128.4M | $151.4M | $144.7M | $115.8M |
| Short-term investments | $192.1M | $199.4M | $180.2M | $129.8M | $377.9M | $347.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.43B | $1.50B | $1.45B | $1.42B | $1.38B | $1.35B |
| Total liabilities | $396.9M | $423.9M | $390.9M | $370.1M | $318.5M | $316.6M |
| Shareholders' equity | $1.03B | $1.08B | $1.06B | $1.05B | $1.06B | $1.03B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology